Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/ Akt Signaling Pathway

Background: Oxaliplatin (OXA)-based chemotherapy is generally used to treat human cancers, whereas OXA resistance is a main obstacle for the treatment of colorectal cancer (CRC). Evidence has shown that tanshinone IIA (Tan IIA) could induce apoptosis in CRC cells. However, the role of combination of OXA and Tan IIA on OXA-resistance CRC cells remains unknown. Thus, this study aimed to investigate the effects of Tan IIA in combination with OXA on OXA-resistance CRC cells. Methods: MTT assay, Ki67 immuno fl uorescence staining and fl ow cytometry were used to detect viability, proliferation and apoptosis in OXA-resistant cell line SW480/OXA, respec-tively. The expressions of Bcl-2, Bax, active caspase 3, p-Akt and p-ERK in SW480/OXA cells were detected with Western blot. In vivo animal study was performed fi nally. Results: In this study, the inhibitory effects of OXA on the proliferation and invasion of SW480/ OXA cells were signi fi cantly enhanced by Tan IIA. In addition, Tan IIA obviously enhanced the anti-apoptosis effects of OXA on SW480/OXA cells via decreasing the levels of Bcl-2, p-Akt and p-ERK, and increasing the levels of Bax and active caspase 3. In vivo experiments con fi rmed that Tan IIA enhanced OXA sensitivity in SW480/OXA xenograft model. Conclusion: We found that Tan IIA could reverse OXA resistance in OXA-resistance CRC cells. Therefore, OXA combined with Tan IIA might be considered as a therapeutic approach for the treatment of OXA-resistant CRC.

[1]  Xudong Zhang,et al.  miR-182 contributes to cell proliferation, invasion and tumor growth in colorectal cancer by targeting DAB2IP. , 2019, The international journal of biochemistry & cell biology.

[2]  Baofeng Yu,et al.  Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling , 2019, Molecules.

[3]  R. Yamashita,et al.  Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy , 2019, BMC Cancer.

[4]  L. Ellis,et al.  Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress , 2019, Scientific Reports.

[5]  Weifei Fan,et al.  FLOT1 promotes tumor development, induces epithelial–mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma , 2019, Thoracic cancer.

[6]  Miao Yu,et al.  Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer , 2019, OncoTargets and therapy.

[7]  Yuelong Wang,et al.  Improved anti‐colorectal carcinomatosis effect of tannic acid co‐loaded with oxaliplatin in nanoparticles encapsulated in thermosensitive hydrogel , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  Ying Gu,et al.  Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways. , 2018, Oncology letters.

[9]  Sheng-Teng Huang,et al.  HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone IIA in human osteosarcoma cells , 2018, Cell Death & Disease.

[10]  M. Pocard,et al.  Pleura and Peritoneum , 2018 .

[11]  U. Gaur,et al.  Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways , 2018, International journal of molecular sciences.

[12]  Hao Zhou,et al.  Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy , 2018, Redox biology.

[13]  D. Yan,et al.  Modulations of Keap1‐Nrf2 signaling axis by TIIA ameliorated the oxidative stress‐induced myocardial apoptosis , 2018, Free radical biology & medicine.

[14]  Fangfang Wang,et al.  Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. , 2017, The Biochemical journal.

[15]  Ye Li,et al.  Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways , 2017, Redox biology.

[16]  Yong Wang,et al.  Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells , 2017, Oncotarget.

[17]  Lixia Xu,et al.  Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[18]  Zheng Hu,et al.  AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling , 2017, Oncotarget.

[19]  S. Friedman,et al.  Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. , 2017, Gastroenterology.

[20]  Y. Zhang,et al.  The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma , 2017, Scientific Reports.

[21]  H. Kuo,et al.  The Association of CXC Receptor 4 Mediated Signaling Pathway with Oxaliplatin-Resistant Human Colorectal Cancer Cells , 2016, PloS one.

[22]  Xiaoling Li,et al.  Dual Drug Loaded Biodegradable Nanofibrous Microsphere for Improving Anti-Colon Cancer Activity , 2016, Scientific Reports.

[23]  K. Ahn,et al.  Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction. , 2016, International journal of oncology.

[24]  X. Liu,et al.  A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin , 2015, Pathology & Oncology Research.

[25]  Wei Chen,et al.  Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines. , 2014, Oncology reports.

[26]  Antonio Gasbarrini,et al.  Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. , 2013, European journal of cancer.

[27]  Fang Wen,et al.  Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. , 2011, Oncology reports.

[28]  Yu-hong Li,et al.  Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. , 2010, Oncology reports.

[29]  Mengtao Zhou,et al.  Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells , 2009, Acta Pharmacologica Sinica.

[30]  T. Satou,et al.  Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. , 2009, Experimental cell research.

[31]  R. Pi,et al.  Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. , 2007, European journal of pharmacology.

[32]  M. Rothenberg.  Efficacy of oxaliplatin in the treatment of colorectal cancer. , 2000, Oncology.